A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY
PPD, Parmaceutical Product Development S.L.
Pathology and candidate patients
Dr. Luís Martí Bonmatí
Hospital Quirónsalud Valencia.
Active. Start date 2013.
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the Diagnostic Imaging team by sending an email to the address: firstname.lastname@example.org